Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review by FDA for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
